Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
Myriad Genetics (NASDAQ: MYGN) expanded its MyRisk® Hereditary Cancer Test on Nov 10, 2025 to include genes referenced in NCCN and ASCO guidelines.
The updated MyRisk panel now includes 63 genes covering more than 11 cancer types, and the company says it includes 100% of genes strongly recommended by national oncology guidelines to support treatment decisions, surveillance planning, and family risk assessment.
Results are available via paper requisition, the Myriad patient portal and multiple EMR platforms including EPIC.
Myriad Genetics (NASDAQ: MYGN) ha ampliato il suo test MyRisk® Hereditary Cancer Test il 10 novembre 2025 per includere geni citati nelle linee guida NCCN e ASCO.
Il pannello MyRisk aggiornato include ora 63 geni che coprono più di 11 tipi di cancro, e l'azienda afferma che comprende il 100% dei geni fortemente raccomandati dalle linee guida oncologiche nazionali per supportare le decisioni di trattamento, la pianificazione della sorveglianza e la valutazione del rischio familiare.
I risultati sono disponibili tramite richiesta cartacea, il portale paziente di Myriad e diverse piattaforme EMR tra cui EPIC.
Myriad Genetics (NASDAQ: MYGN) amplió su prueba de cáncer hereditario MyRisk® el 10 de noviembre de 2025 para incluir genes referenciados en las guías NCCN y ASCO.
El panel MyRisk actualizado incluye ahora 63 genes que abarcan más de 11 tipos de cáncer, y la empresa dice que incluye el 100% de los genes fuertemente recomendados por las guías oncológicas nacionales para apoyar las decisiones de tratamiento, la planificación de la vigilancia y la evaluación del riesgo familiar.
Los resultados están disponibles a través de la solicitud en papel, el portal para pacientes de Myriad y múltiples plataformas EMR, incluido EPIC.
마이어드 제네틱스(Myriad Genetics, NASDAQ: MYGN)는 NCCN 및 ASCO 가이드라인에 언급된 유전자를 포함하도록 2025년 11월 10일에 MyRisk® 유전암 위험 검사(MyRisk Hereditary Cancer Test)를 확장했습니다.
업데이트된 MyRisk 패널은 이제 63개 유전자를 포함하여 11종 이상의 암 유형을 다루며, 회사는 전국 암학 가이드라인에서 강하게 권장하는 유전자의 100%를 포함한다고 말해 치료 결정, 모니터링 계획 및 가족 위험 평가를 지원합니다.
결과는 종이 의뢰, Myriad 환자 포털 및 EPIC를 포함한 여러 EMR 플랫폼을 통해 제공됩니다.
Myriad Genetics (NASDAQ: MYGN) a étendu son test MyRisk® pour les cancers héréditaires le 10 novembre 2025 afin d'inclure les gènes référencés dans les directives NCCN et ASCO.
Le panel MyRisk mis à jour comprend désormais 63 gènes couvrant plus de 11 types de cancer, et la société affirme qu'il inclut 100% des gènes fortement recommandés par les directives oncologiques nationales pour soutenir les décisions de traitement, la planification de la surveillance et l'évaluation du risque familial.
Les résultats sont disponibles via une demande sur papier, le portail patient Myriad et plusieurs plateformes EMR, dont EPIC.
Myriad Genetics (NASDAQ: MYGN) hat seinen MyRisk®-Erbkrankheiten-Test am 10. November 2025 erweitert, um Gene aufzunehmen, die in den NCCN- und ASCO-Leitlinien referenziert werden.
Das aktualisierte MyRisk-Panel umfasst jetzt 63 Gene, die mehr als 11 Krebsarten abdecken, und das Unternehmen sagt, es enthielte 100% der Gene, die von nationalen onkologischen Leitlinien stark empfohlen werden, um Behandlungsentscheidungen, Überwachungsplanung und familiäre Risikobewertung zu unterstützen.
Ergebnisse sind per Papierabfrage, dem Myriad-Kundenportal und mehreren EMR-Plattformen verfügbar, einschließlich EPIC.
ميرِيد جينيتكس (ناسداك: MYGN) وسَّعت اختبار سرطان الوراثة MyRisk® في 10 نوفمبر 2025 ليشمل جينات مذكورة في NCCN وASCO.
يضم لوحة MyRisk المحدثة الآن 63 جيناً يغطي أكثر من 11 نوع سرطان، وتقول الشركة إنه يتضمن 100% من الجينات التي توصي بها الإرشادات الوطنية للسرطان بقوة لدعم قرارات العلاج، وتخطيط المراقبة، وتقييم مخاطر العائلة.
النتائج متاحة عبر طلب ورقي، وبوابة مرضى Myriad، والعديد من منصات السجلات الطبية الإلكترونية بما في ذلك EPIC.
- Panel expanded to 63 genes
- Coverage across >11 cancer types
- Includes 100% of genes strongly recommended by national oncology guidelines
- EMR integration with EPIC and OncoEMR for clinician access
- None.
Insights
Expanded MyRisk adds guideline-referenced genes, increasing clinical utility for hereditary cancer testing.
Myriad Genetics broadened the MyRisk panel to include 63 genes now aligned with NCCN and ASCO guidance, aiming to support treatment choices, surveillance planning, and family risk assessment. The announcement states these genes are "strongly associated with cancer risk" and framed as having "clear clinical actionability," which explains the business mechanism: broadened gene coverage increases the test's relevance across more cancer types and clinical scenarios.
Key dependencies and risks include uptake by ordering clinicians and seamless report integration into workflows; the release notes electronic access via EPIC, OncoEMR, and a patient portal, which reduces friction. The update's value hinges on interpretation quality and whether the additions change clinical management decisions; the company emphasizes its interpretive capabilities as the differentiator.
Watch for measurable adoption signals and guideline-aligned management changes over the next 6–12 months, and check the Myriad gene table for the full gene list and associated management recommendations; the
SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced MyRisk® Hereditary Cancer Test—the gold standard in germline testing—has been expanded to include genes referenced in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)1 and guidelines from American Society of Clinical Oncology (ASCO).
These genes are strongly associated with cancer risk and may have clear clinical actionability, supporting the goal that each addition to the panel provides meaningful insights for patient care. The updated MyRisk panel now includes 63 carefully selected genes across more than 11 cancer types, reflecting Myriad’s commitment to meeting evolving clinical needs.
“While many labs can detect DNA variants, it’s the interpretation of those variants that truly impacts patient care and that is where Myriad excels,” said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics. “Medical societies recommend genes for testing when they influence treatment decisions, and those are the genes we prioritize in the MyRisk Test. I’m delighted that these clinically significant genes are now part of the core MyRisk panel. As guidelines evolve, Myriad remains committed to providing clinicians and genetic counselors with insights of high clinical utility to guide patient care.”
The MyRisk Test is designed to deliver clinical value at every step of the cancer care continuum by helping treatment decisions, surveillance planning, and family risk assessment across multiple cancer types. Clinicians can conveniently order, receive, and review expanded MyRisk Test results directly through paper Test Requisition Forms and reports, the Myriad patient portal and several electronic medical record platforms, including EPIC and OncoEMR. To view the full gene list and associated medical management recommendations, please visit the Myriad gene table.
- NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s commitment to meeting evolving clinical needs and providing clinicians and genetic counselors with insights of high clinical utility to guide patient care, and how the MyRisk Test is designed to deliver clinical value at every step of the cancer care continuum. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
FAQ
What change did Myriad Genetics (MYGN) announce on Nov 10, 2025 about the MyRisk test?
How many cancer types does the updated MyRisk (MYGN) panel cover?
Does the MyRisk test (MYGN) include genes recommended by NCCN guidelines?
How can clinicians order and receive MyRisk (MYGN) test results after the Nov 10, 2025 update?
What clinical uses does Myriad cite for the expanded MyRisk (MYGN) panel?
Where can investors find the full gene list and management recommendations for MyRisk (MYGN)?
